Which Are the Top Emerging Companies in the Dermatology Drugs Market in 2025?

The dermatology drugs industry is undergoing rapid change, driven by innovation, strategic partnerships, and the growing need for advanced treatments addressing chronic and rare skin conditions. While traditional pharmaceutical giants continue to dominate, several emerging and mid-tier players are making strong advances with targeted therapies, biologics, and cutting-edge technologies. These companies are shaping the next growth wave of the dermatology drugs industry creating new opportunities for innovation and improved patient care.

Key Emerging & Established Players in Dermatology Drugs

Arcutis Biotherapeutics

Arcutis is a clinical-stage biopharmaceutical company specializing in immune-mediated skin diseases. Its flagship product, roflumilast cream, is being developed as a next-generation non-steroidal topical therapy for psoriasis and atopic dermatitis, aiming to provide an alternative to corticosteroids. Arcutis is also advancing pipeline candidates for seborrheic dermatitis and vitiligo, focusing on therapies with fewer side effects and long-term safety for patients requiring chronic treatment.

Dermira (Eli Lilly subsidiary)

Acquired by Eli Lilly, Dermira maintains a strong identity in dermatology. The company has historically focused on acne, psoriasis, and hyperhidrosis. Its key product Qbrexza (glycopyrronium cloth) offers a novel topical approach for hyperhidrosis, while Eli Lilly leverages Dermira’s pipeline to strengthen its immunology and dermatology portfolio. The integration has allowed Dermira to scale its innovations globally, making it a notable player bridging biotech agility with big pharma resources.

AnaptysBio

AnaptysBio is advancing antibody-based therapies that address inflammatory and autoimmune conditions, with dermatology as a core focus. The company’s clinical pipeline includes anti-IL-36R antibodies for generalized pustular psoriasis (a rare but severe condition) and other immuno-dermatological disorders. Its strategy revolves around precision immunology and leveraging biologics to treat conditions where traditional small molecules are inadequate.

Connect Biopharma

Headquartered in China and the U.S., Connect Biopharma develops therapies that modulate T-cell activity. Its lead drug candidate, CBP-201, is being investigated for atopic dermatitis and asthma, addressing large unmet needs in inflammatory skin diseases. By targeting cytokine signaling pathways, Connect Biopharma aims to bring differentiated, accessible treatments to global markets, particularly in regions with high prevalence of eczema.

Krystal Biotech

Krystal is a pioneer in gene therapy for dermatology, with a focus on rare, inherited skin disorders. Its leading program, beremagene geperpavec (B-VEC), targets dystrophic epidermolysis bullosa (DEB), a devastating genetic skin disease with no curative treatments. By harnessing viral vector-based delivery, Krystal is opening a new frontier in dermatology. The company’s success could set the stage for wider use of gene therapy in treating chronic dermatological conditions.

Journey Medical Corporation

Journey Medical, a subsidiary of Fortress Biotech, commercializes and develops products focused solely on dermatology. Its portfolio includes FDA-approved therapies for acne, rosacea, seborrheic dermatitis, and actinic keratosis. Journey’s strategy is to acquire, develop, and commercialize proven dermatology assets, making it a growth-driven company that supports dermatologists with both branded and generic treatment options.

Revance Therapeutics

Revance is known for its Daxxify (daxxibotulinumtoxinA), a long-lasting neuromodulator for aesthetics, but the company is expanding its footprint in medical dermatology. Its injectable and topical innovations bridge aesthetic and therapeutic dermatology, addressing conditions such as cervical dystonia, glabellar lines, and potentially skin-related nerve disorders. Revance’s model combines dermatology drugs with a strong aesthetics portfolio, offering unique cross-market synergies.

LEO Pharma A/S

A global pure-play dermatology company headquartered in Denmark, LEO Pharma has over 100 years of heritage in skin health. Its focus spans psoriasis, eczema, atopic dermatitis, and rare skin conditions. Key products include Enstilar foam and Protopic ointment. The company invests heavily in biologics, with tralokinumab (Adtralza) emerging as a flagship treatment for atopic dermatitis. With operations in 100+ countries, LEO combines innovation and patient-centered care, positioning itself as a global leader in dermatology.

GlaxoSmithKline plc (GSK)

GSK integrates dermatology within its immunology and inflammation portfolio, focusing on treatments that address atopic dermatitis and chronic urticaria. Its biologic Omalizumab (Xolair), co-developed with Novartis, is widely used for allergic asthma and chronic hives but has dermatological relevance. GSK continues to invest in immuno-dermatology research, leveraging its R&D capabilities to expand treatment options for inflammatory skin diseases.

Novartis AG

Novartis is a dominant player in dermatology with Cosentyx (secukinumab), a blockbuster biologic for psoriasis and psoriatic arthritis. Beyond psoriasis, Novartis is investing in pipeline drugs targeting hidradenitis suppurativa, urticaria, and other dermatological conditions. Its biologics-driven dermatology strategy focuses on immune modulation, setting high standards for efficacy and long-term patient safety.

AbbVie Inc.

AbbVie has established itself as a dermatology leader, anchored by its blockbuster Humira (adalimumab) and its successors Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are transforming treatment for psoriasis, atopic dermatitis, and other autoimmune skin conditions. AbbVie invests heavily in dermatology-focused immunology R&D, ensuring a robust pipeline that balances biologics, small molecules, and novel mechanisms of action.

Galderma S.A.

Headquartered in Switzerland, Galderma is a pure-play dermatology leader with one of the most diverse portfolios in the sector. Its therapeutic segment covers acne (Epiduo), rosacea (Soolantra), psoriasis, and atopic dermatitis, while its aesthetic dermatology division is known for Restylane fillers and Dysport neuromodulator. Galderma’s balanced approach—medical, therapeutic, and aesthetic dermatology—positions it as a comprehensive global dermatology brand.

Conclusion

The dermatology drugs market is being reshaped by both specialized biotech innovators and established pharmaceutical leaders. Emerging companies such as Arcutis Biotherapeutics, Krystal Biotech, and Connect Biopharma are disrupting with niche therapies, while global giants like AbbVie, Novartis, LEO Pharma, and Galderma continue to dominate through biologics and expansive pipelines. Together, these players are accelerating the transition toward safer, more effective, and highly personalized dermatological treatments, ensuring that patients worldwide benefit from next-generation innovations.